Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Jazz Pharmaceuticals (JAZZ) PT Lowered to $200 at Cowen
November 7, 2018 8:57 AM ESTCowen analyst Ken Cacciatore lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $200.00 (from $220.00) while maintaining a Outperform rating.
... MoreJazz Pharmaceuticals (JAZZ) PT Lowered to $203 at BMO Capital
November 7, 2018 8:56 AM ESTBMO Capital analyst Gary Nachman lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $203.00 (from $206.00) while maintaining a Outperform rating.
The analyst commented, "JAZZ reported mixed 3Q results with revenue of $469mm below BMO/consensus $478mm/$483mm, and adj. EPS of $3.58 ahead of... More
Jazz Pharmaceuticals (JAZZ) PT Lowered to $184 at RBC Capital
November 7, 2018 7:22 AM ESTRBC Capital analyst Randall Stanicky lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $184.00 (from $194.00) while maintaining a Outperform rating.
... More